Incannex Healthcare stock tumbles after filing $100M offering
GSK plc (LSE/NYSE:GSK), in partnership with iTeos Therapeutics, Inc., has announced the termination of the development program for belrestotug, an investigational anti-TIGIT monoclonal antibody. The decision followed interim results from two phase 2 studies, GALAXIES Lung-201 and GALAXIES H&N-202, which did not meet predefined efficacy criteria. Consequently, all study cohorts involving belrestotug will be discontinued.
The pharmaceutical giant, based in London, has a strategic focus on oncology, aiming to improve survival and quality of life for patients with cancer. Despite this setback, GSK’s oncology pipeline includes promising programs such as antibody-drug conjugates targeting B7-H3 and B7-H4, and IDRX-42, a selective KIT tyrosine kinase inhibitor.
This update was provided in a Form 6-K filed with the Securities and Exchange Commission on Tuesday, May 13, 2025. The document also included cautionary statements about forward-looking projections, highlighting the inherent risks and uncertainties that could cause actual results to differ from expectations. GSK’s commitment to advancing healthcare through science and technology remains steadfast as they continue to explore other avenues in their broad research portfolio. The information disclosed is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.